Tumor Xenograft Model with siRNA Nanoparticle Treatment
Objective: Assess selective tumor uptake of ligand-targeted nanoparticles carrying VEGF R2-targeting siRNA, protein expression inhibition, and effects on angiogenesis and tumor growth in tumor-bearing mice
This is a Tumor Xenograft Model with siRNA Nanoparticle Treatment protocol using mouse as the model organism. The procedure involves 6 procedural steps, 5 materials. Extracted from a 2004 paper published in Nucleic Acids Research.
Model and subjects
mouse • Not specified • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Nanoparticle construction • In vitro cell delivery and activity assessment • Intravenous administration
Primary readouts
- Selective tumor uptake of nanoparticles
- siRNA sequence-specific inhibition of protein expression within tumor
- Inhibition of tumor angiogenesis
- Inhibition of tumor growth rate
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Nanoparticle construction
Self-assembling nanoparticles with siRNA were constructed using polyethyleneimine (PEI) that is PEGylated with an Arg-Gly-Asp (RGD) peptide ligand attached at the distal end of the polyethylene glycol (PEG)
Note: The RGD peptide ligand targets tumor neovasculature expressing integrins
View evidence from paper
“Self-assembling nanoparticles with siRNA were constructed with polyethyleneimine (PEI) that is PEGylated with an Arg-Gly-Asp (RGD) peptide ligand attached at the distal end of the polyethylene glycol (PEG)”
In vitro cell delivery and activity assessment
Cell delivery and activity of PEGylated PEI was evaluated for siRNA sequence specificity and dependence on peptide ligand presence
Note: Activity could be competed by free peptide, demonstrating ligand-dependent targeting
View evidence from paper
“Cell delivery and activity of PEGylated PEI was found to be siRNA sequence specific and depend on the presence of peptide ligand and could be competed by free peptide”
Intravenous administration
Ligand-targeted sterically stabilized nanoparticles carrying VEGF R2-targeting siRNA were administered intravenously into tumor-bearing mice
Note: Administration route is intravenous
View evidence from paper
“Intravenous administration into tumor-bearing mice gave selective tumor uptake, siRNA sequence-specific inhibition of protein expression within the tumor”
Assessment of tumor uptake
Selective tumor uptake of nanoparticles was assessed following intravenous administration
Note: Uptake was selective to tumor tissue
View evidence from paper
“Intravenous administration into tumor-bearing mice gave selective tumor uptake”
Protein expression analysis
siRNA sequence-specific inhibition of protein expression within the tumor was evaluated
Note: Inhibition was sequence-specific
View evidence from paper
“siRNA sequence-specific inhibition of protein expression within the tumor”
Assessment of angiogenesis and tumor growth
Inhibition of both tumor angiogenesis and growth rate was evaluated following nanoparticle treatment
Note: Both angiogenesis and tumor growth rate were measured as outcome parameters
View evidence from paper
“inhibition of both tumor angiogenesis and growth rate”